Form 4: Ironwood Pharmaceuticals Director Jon Duane Acquires 45,000 Shares Through Restricted Stock Grant

Ironwood Pharmaceuticals, Inc. Director Jon R. Duane has acquired 45,000 shares of Class A Common Stock as a restricted stock grant, increasing his direct beneficial ownership to 190,339 shares.

Summary

• Jon R. Duane, a Director at Ironwood Pharmaceuticals, Inc. (IRWD), acquired 45,000 shares of Class A Common Stock on June 10, 2025.
• The acquisition was a restricted stock grant, with a reported price of $0 per share, indicating it is part of a compensation plan.
• This grant was made pursuant to the company's Second Amended and Restated Non-employee Director Compensation Policy, which became effective on January 1, 2024.
• Following this transaction, Mr. Duane's direct beneficial ownership of Ironwood Pharmaceuticals' Class A Common Stock stands at 190,339 shares.
• The restricted stock is set to vest in full on the day immediately preceding the date of the annual meeting of stockholders for the next calendar year.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a routine, expected compensation event for a director, aligning their interests with shareholders. It does not indicate any negative operational or financial news.

Positives

• The acquisition of 45,000 shares by Director Jon R. Duane aligns his interests further with those of shareholders, as his compensation is tied to the company's equity performance.
• The grant is part of a pre-existing, publicly disclosed compensation policy (Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024), indicating a structured approach to director remuneration.

Negatives

• No direct negative financial implications for the company are immediately apparent from this routine director compensation grant.

Risks

• The document, a Form 4, does not detail specific company-wide risks. The inherent risk for the director is the fluctuation in the value of the granted shares until vesting.

Future Outlook

The restricted stock grant is scheduled to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, indicating a future milestone for the director's compensation.

Industry Context

This Form 4 filing reflects a routine compensation event for a director within the pharmaceutical industry. Such equity grants are a common practice to align executive and director interests with long-term shareholder value, consistent with compensation strategies across various sectors, including biotechnology and pharmaceuticals.

Corporate Governance

Related Party Transactions

• The restricted stock grant to a director is a related party transaction, but it is a standard form of compensation disclosed as per regulatory requirements.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying a portion of their compensation to the company's stock performance. It is a non-dilutive event at the time of grant, but future vesting and potential sale could impact share float.
• Employees: No direct impact on employees is indicated by this director compensation filing.

Next Steps

• The restricted stock granted to Jon R. Duane is expected to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, SEC Form 4, Director Compensation, Restricted Stock Grant, Insider Trading, Equity Acquisition, Pharmaceuticals, Biotechnology